Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Disodium edetate/ethyl alcohol/minocycline - Citius Pharmaceuticals

Next Previous
Drug Profile

Disodium edetate/ethyl alcohol/minocycline - Citius Pharmaceuticals

Alternative Names: Alcohol/edetate-disodium/minocycline; Alcohol/minocycline/disodium-edetate; Alcohol/minocycline/edetate-disodium; Disodium-edetate/alcohol/minocycline; Disodium-edetate/ethanol/minocycline; Disodium-edetate/minocycline/alcohol; Disodium-edetate/minocycline/ethanol; Edetate-disodium/alcohol/minocycline; Edetate-disodium/ethanol/minocycline; Edetate-disodium/minocycline/alcohol; Edetate-disodium/minocycline/ethanol; Mino-Lok; Mino-Lok Therapy (MLT); Minocycline-EDTA-EtOH; Minocycline/alcohol/disodium-edetate; Minocycline/alcohol/edetate-disodium; Minocycline/disodium-edetate/alcohol; Minocycline/disodium-edetate/ethanol; Minocycline/edetate-disodium/alcohol; Minocycline/edetate-disodium/ethanol; Minocycline/ethanol/disodium-edetate; Minocycline/ethanol/edetate-disodium; MinoLok

Latest Information Update: 15 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Citius Pharmaceuticals Inc; Leonard Meron Biosciences; University of Texas M. D. Anderson Cancer Center
  • Class Alcohols; Anti-infectives; Antibacterials; Anticoagulants; Antiseptics; Disinfectants; Small molecules; Tetracyclines
  • Mechanism of Action Chelating agents; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Catheter infections

Most Recent Events

  • 10 Jul 2024 Citius Pharmaceuticals plans to prepare a submission and schedule a type B meeting with the US FDA
  • 21 May 2024 Efficacy and adverse events data from a phase III trial in Catheter infections released by Citius Pharmaceuticals
  • 14 May 2024 Leonard-Meron Biosciences completes phase-III trial in Catheter infections (In children, In the elderly, In adults, Adjunctive therapy) in USA, India and Puerto Rico (unspecified route) before May 2024 (NCT02901717)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top